RFA-NS-26-030
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Summary
NINDS Genomic and Biologic Therapeutics for Alzheimer's Disease-Related Dementias
NINDS seeks to advance genomic and biologic therapeutic candidates for Alzheimer's Disease-Related Dementias (ADRD) through translational development and clinical readiness. The program targets a critical bottleneck: while breakthroughs in gene therapy and biologic therapeutics have created new treatment opportunities, progress stalls at challenges in delivery, safety, manufacturability, and regulatory preparation. Supported research spans optimization of therapeutic design through IND-enabling studies and early clinical evaluation, with emphasis on frontotemporal degeneration (FTD), Lewy body dementia (LBD), and vascular cognitive impairment and dementia (VCID). Projects should generate pharmacology, toxicology, biodistribution, and in vivo efficacy data; refine manufacturability; and build the complete regulatory package for IND submissions and first-in-human clinical studies. This aligns with ADRD Summit priorities for accelerating disease-modifying therapeutics.
- Who can apply: Not stated; note: applications are not currently being solicited, though notice is provided for collaboration development.
- Funding & project length: Not stated.
- Award mechanism: Not stated.
- Key dates: Not stated.
- Best fit for: Genomic medicine, pharmacology, and translational neuroscience researchers with preclinical therapeutic candidates ready for optimization and regulatory pathway planning.
Insights (6)
Application Timeline Ambiguity Creates Submission Risk and Planning Uncertainty
The FOA explicitly states 'Applications are not being solicited at this time,' yet describes a funded program with specific priorities and mechanisms. This creates critical uncertainty: there is no announced submission deadline, no clear pathway to apply, and no confirmation that a formal RFP will be issued. Applicants investing in collaboration and project development now face the risk of a delayed or modified solicitation that may alter scope or eligibility.
Genomic and Biologic Therapeutics Expertise Essential; Translational Pipeline Maturity Required
Success requires demonstrated competency across the full translational arc—from therapeutic optimization through IND-enabling studies and potentially FIH trials. Applicants with preliminary data showing pharmacology, toxicology, biodistribution, and in vivo efficacy in ADRD models (particularly FTD, LBD, or VCID) will be most competitive. Weak or missing data in any of these domains will significantly disadvantage an application.
Regulatory and Manufacturing Partnerships Likely Essential for Competitive Applications
The program explicitly emphasizes manufacturability, regulatory readiness, and IND submission support. Applicants without established relationships with GMP manufacturers, regulatory consultants, or clinical trial infrastructure may struggle to credibly propose the full scope of work. Multi-PI teams pairing basic science with translational/regulatory expertise are strategically advantageous.
Early-Stage Investigators May Face Disadvantage in Translational Development Scope
The program targets projects spanning optimization through early clinical evaluation—a scope typically requiring established infrastructure, regulatory experience, and institutional support. ESIs without prior IND submissions or clinical trial experience may find it difficult to propose credible, comprehensive translational plans. This mechanism appears better suited to established translational researchers or teams with complementary senior expertise.
Narrow Disease Focus and Translational Specificity Will Concentrate Competition
The program targets three specific dementia subtypes (FTD, LBD, VCID) and genomic/biologic modalities only—excluding small-molecule approaches. This specificity reduces the applicant pool but intensifies competition among those with relevant expertise. Applicants working on broader ADRD targets or non-genomic/biologic approaches should not apply.
Preliminary Data on Delivery, Safety, and Manufacturability Differentiates Strong Applications
The FOA identifies delivery, safety, manufacturability, and clinical readiness as key limiting factors in the field. Applicants with preliminary evidence addressing these specific bottlenecks—not just efficacy—will stand out. Data demonstrating solutions to CNS delivery, off-target toxicity mitigation, or scalable manufacturing will strengthen competitiveness significantly.
Key Facts
Deadline
—
Posted
Thu, February 12, 2026
Expected Awards
3
Keywords
Research Areas
Gotchas (2)
Applications are explicitly not being solicited at this time, yet the FOA describes a funded program. This creates ambiguity about whether applications can actually be submitted and under what timelin
95%
Source Text
“Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.”
Program prioritizes specific disease areas (FTD, LBD, VCID) within ADRD but does not explicitly state whether applications for other ADRD-related dementias are in-scope or out-of-scope.
85%
Source Text
“The program is aligned with priorities from the ADRD Summits, including acceleration of disease-modifying therapeutic development in frontotemporal degeneration (FTD), Lewy body dementia (LBD), and vascular contributions to cognitive impairment and dementia (VCID).”